(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) announced on Wednesday that it has agreed to sell a Rare Pediatric Disease Priority Review Voucher for $203 million.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.